Acorda Therapeutics reports preliminary results, provides 2014 guidance

Shares of Acorda Therapeutics (ACOR +4.2%) are higher in morning trading after the company provided preliminary financial results in connection with the JPMorgan Healthcare Conference.

Q4 and FY Ampyra net sales: $84M and $302M, respectively.

2014 Ampyra net sales guidance: $328-335M.

2014 opex guidance: R&D, $60-70M; SG&A, $180-190M.

2014 Zanaflex guidance and ex-U.S. Fampyra revenue: $25M


From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs